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Pretransplant remission status in patients with acute myeloid leukemia (AML) is 1 of the most important
factors determining their outcomes after allogeneic hematopoietic cell transplantation (allo-HCT). Most
patients are in complete remission with full hematologic recovery (CR) before undergoing allo-HCT. However,
some patients achieve CR without recovery of platelet count (CRp) or a morphologic leukemia-free state
(MLFS), deﬁned as meeting all CR criteria without recovery of both neutrophil and platelet counts. Currently,
there is a paucity of data regarding transplant outcomes in AML patients achieving MLFS after chemotherapy.
To address this question, we evaluated transplant outcomes in 270 AML patients who received 6/6 HLA-
matched sibling or 10/10 HLA-matched unrelated donor transplantation at a single institution between
2006 and 2013. Of our 270 patients, 206 were in CR, 45 were in CRp, and 19 were in MLFS before allo-HCT.
Patients in CR, CRp, or MLFS had similar 3-year overall survival rates (49%, 46%, and 47%, respectively; P ¼ .88)
and 3-year event-free survival rates (45%, 36%, and 40%, respectively; P ¼ .53). However, the cumulative
incidence of nonrelapse mortality was signiﬁcantly higher in patients in MLFS compared with those in CR
(58% versus 22%, P ¼ .0004), whereas the cumulative incidence of relapse in patients in MLFS was signiﬁcantly
lower compared with those in CR (11% versus 36%, P ¼ .03). Our results suggest that survival outcomes in AML
patients are not inﬂuenced by degree of hematologic recovery before allo-HCT.
 2015 American Society for Blood and Marrow Transplantation.INTRODUCTION
Despite the advancements of biomedical knowledge and
treatment of acute myeloid leukemia (AML), patients with
AML continue to have poor survival outcomes, with 5-year
overall survival (OS) rates still close to only 25%. The prog-
nosis is worse for patients older than 60 years, whose 5-year
OS rates are only 5% to 10% [1]. With new knowledge on
molecular and genomic abnormalities, such as mutations in
the FLT3, TP53, IDH1/2, TET2, and MLL genes, we also know
these AML-speciﬁc factors affect overall prognosis [2-12].dgments on page 1429.
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ty for Blood and Marrow Transplantation.In addition to age and genetic mutations, remission status
after chemotherapy is also important in determining prog-
nosis. Achievement of complete remission (CR) after induc-
tion treatment has been shown to correlate with improved
survival in AML patients [13]. Part of the deﬁnition of CR
requires hematologic recovery that include a platelet count
greater than 100,000/mL and an absolute neutrophil count
(ANC) greater than 1000/mL [14]. In contrast, studies have
shown that CR with incomplete hematologic recovery is
associated with reduced OS and increased risk of relapse
[13,15-19]. However, most of these studies focused
predominantly on patients who did not receive allogeneic
hematopoietic cell transplantation (allo-HCT). Furthermore,
there is currently a paucity of data on outcomes in AML pa-
tients who achieve a morphologic leukemia-free state
(MLFS), deﬁned as meeting all CR criteria except for
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< 1000/mL) [14,20].
It is currently a common practice to wait for complete
hematologic recovery before proceeding with allo-HCT in
most AML patients. However, this approach potentially in-
creases the risk of infectious and noninfectious (bleeding,
transfusion-related adverse events, etc.) complications,
which could potentially make these patients ineligible for
transplant and consequently jeopardize their chances of
long-term survival. To address the question of whether
achieving MLFS adversely affects survival and relapse in AML
patients who undergo allo-HCT, we retrospectively analyzed
the post-transplant outcomes of AML patients based on the
extent of hematologic recovery after pretransplant
chemotherapy.
METHODS
Study Population
The study included 503 consecutive AML patients who underwent their
ﬁrst allo-HCT at Washington University Medical Center in St. Louis between
2006 and 2013. This study was approved by the Institutional Review Board
of Washington University School of Medicine, St. Louis.
Patient, donor, and transplant characteristics were collected and retro-
spectively entered into theWashington University School of Medicine Blood
and Marrow Transplant Database. Of the 503 patients, data from 270 pa-
tients were analyzed based on the following eligibility criteria: (1) 6/6match
at HLA loci A, B, and DRB1 by low-resolution genotyping [21] in related
donor transplantation or 10/10 match at HLA loci A, B, C, DRB1, and DQB1 by
high-resolution genotyping [22] in unrelated donor transplantation; (2) use
of unmodiﬁed stem cells/nonmanipulated grafts; and (3) no evidence of
active disease (bone marrow blasts < 5%) based on last bone marrow biopsy
before transplant.
The type of conditioning regimen was classiﬁed based on consensus
deﬁnition of conditioning regimen intensity [23]. Reduced-intensity and
nonmyeloablative regimens were grouped together under the reduced-
intensity conditioning (RIC) cohort. The HCT-speciﬁc comorbidity index
(HCT-CI) score was calculated for all patients and categorized into 3 risk
groups: low risk deﬁned as score of 0, intermediate risk deﬁned as score of 1
to 2, and high risk deﬁned as score of 3 or greater [24].
Deﬁnitions
Based on hematologic recovery before initiating pretransplant condi-
tioning, patients were classiﬁed into 3 cohorts: (1) CR, (2) CR with incom-
plete platelet count recovery (CRp), and (3) MLFS. CR was deﬁned as follows:
(1) bone marrow blasts less than 5%, (2) ANC greater than 1000/mL, (3)
platelet count greater than 100,000/mL, (4) absence of blasts with Auer rods,
(5) absence of extramedullary disease, and (6) independence of RBC trans-
fusions, according to response criteria from the International Working
Group [14]. CR was not further classiﬁed into cytogenetic CR or molecular
CR. CRp was deﬁned as meeting all CR criteria except for platelet count less
than 100,000/mL. MLFS was deﬁned as meeting all CR criteria except for a
combination of ANC less than 1000/mL and platelet count less than 100,000/
mL. Pretransplant bone marrow was also evaluated for the persistence of
cytogenetic (ie, translocations, chromosomal deletions) and molecular (ie,
FLT3, NPM1, CEBPA mutations) abnormalities present at the time of original
diagnosis.
Acute graft-versus-host disease (aGVHD) was diagnosed based on signs
and symptoms and graded according to accepted criteria [25]. Chronic
GVHD (cGVHD) was graded using National Institutes of Health consensus
criteria [26].
Etiology of AML was classiﬁed into (1) de novo AML or (2) secondary
AML, deﬁned as occurring from treatment (radiation, alkylating agents,
topoisomerase inhibitors) and bone marrow disorders such as myelopro-
liferative neoplasm or myelodysplastic syndrome [14,27]. AML was classi-
ﬁed into good, intermediate, and poor prognostic cohorts based on the
European LeukemiaNet classiﬁcation scheme for cytogenetic and molecular
genetic data [20].
Post-Transplantation Disease Monitoring
Engraftment of the donor cells was determined by PCR assay for short
tandem repeats or ﬂuorescence in situ hybridization from bone marrow
samples and/or peripheral blood mononuclear cells [28]. Complete donor
engraftment was deﬁned as the presence of less than 5% of recipient cells at
30 days after transplant. Mixed chimerism was deﬁned as presence of
greater than 5% but no more than 95% of recipient cells. Patients underwentbonemarrow biopsies after allo-HCT at 30 days and 100 days and then every
6 months or earlier if peripheral blood counts showed abnormal ﬁndings of
concern for relapse. Disease in remission after transplant was deﬁned as
absence of excess blasts on bone marrow biopsy 30 days after transplant.
Extramedullary disease or relapsewas deﬁned by presence of blasts in tissue
biopsy or cerebrospinal ﬂuid.
Study Endpoints and Statistical Analysis
The study end points included 3-year OS, 3-year event-free survival
(EFS), and cumulative incidences of relapse, nonrelapse mortality (NRM),
aGVHD, and cGHVD. OS was deﬁned as the time from transplant to death
from any cause or last follow-up. Those patients alive were censored at the
last follow-up. EFS was deﬁned as the time from transplant to relapse or
death without relapse, whichever occurred ﬁrst, whereas those patients
alive and free of disease were censored at the last follow-up [14].
The distributions of demographic and clinical characteristics across the
3 cohorts (CR, CRp, and MLFS) were compared using the chi-square test,
Kruskall-Wallis rank-sum test, or 1-way analysis of variance as appropriate.
Survival curves by remission status were estimated using the Kaplan-Meier
product-limit method, and the differences in OS or EFS at 3 years were
compared using Klein’s pseudo-value approach [29]. To assess whether
remission status was an independent predictor of OS and EFS, propensity-
score matching was used to adjust for potential confounding effects of pa-
tient characteristics [30]. The propensity scores for achieving CR were
estimated using multivariate logistic regression, including age,
donorepatient sex mismatch, disease etiology, disease status at transplant,
disease classiﬁcation by cytogenetics, conditioning regimen, transplant
type, and antithymocyte globulin regimen. A 3:1 matching (eg, identifying 3
matched patients from a CR cohort for every patients in MLFS cohort) was
used for comparing CR versus MLFS cohorts, whereas a 1:1 matching was
used for CR versus CRp cohorts. The cumulative incidences of NRM and
relapse were calculated using Gray’s subdistribution method to account for
the presence of competing risks [31].
All analyses were 2-sided, and signiﬁcance was set at P ¼ .05. Statistical
analyses were performed using statistical packages cmprsk (http://bio-
www.dfci.harvard.edu/wgray) for competing risk analysis and SAS 9.3 (SAS
Institutes, Cary, NC) for all other analyses.
RESULTS
Patient Characteristics
The distribution of patients among these cohorts was as
follows: 206 in CR, 45 in CRp, and 19 in MLFS. Patient, dis-
ease, and transplant characteristics of these cohorts are
summarized in Table 1. In our entire patient cohort, the
median age was 54 years (range, 17 to 74). There was no
signiﬁcant difference in median age or time between last
chemotherapy and transplant among the 3 individual co-
horts. Likewise, there was no signiﬁcant difference in dis-
tribution by gender, disease prognosis, disease etiology, and
type of transplant. There were 5 signiﬁcant differences be-
tween the cohorts. First, there were more female
donoremale recipient transplants in the MLFS cohort than in
the CR and CRp cohorts (P ¼ .007). Second, a lower per-
centage of patients in the CRp cohort underwent a myeloa-
blative conditioning regimen than in the CR and MLFS
cohorts (P ¼ .024). Third, a higher percentage of patients in
the CRp cohort had a high HCT-CI score (3 or greater) than in
the CR and MLFS cohorts (P ¼ .024). Fourth, a higher per-
centage of patients in the MLFS cohort had pretransplant
bone marrow cellularity of 10% or less than in the CR or CRp
cohorts (P < .001). However, the range of bone marrow
cellularity was wide in all cohorts, with a maximum cellu-
larity of 80% in the MLFS cohort, 90% in the CR cohort, and
70% in the CRp cohort (data not shown). Fifth, there was a
higher percentage of patients in the MLFS cohort who had
persistent cytogenetic and/or molecular abnormalities in
pretransplant bone marrow (P < .001).
The types of chemotherapy regimens immediately before
transplant were relatively similar in distribution for the 3
cohorts, except that high-dose cytarabine was less
commonly used in the MLFS cohort than in the CR and CRp
Table 1
Patient, Donor, and Transplant Characteristics
All Patients Patients in CR Patients in CRp Patients in MLFS P
Number of patients (%) 270 206 (76) 45 (17) 19 (7)
Median patient age, yr (range) 54 (17-74) 53 (17-72) 58 (21-74) 57 (24-73) .085
Patient sex (%) .112
Female 124 (46) 101 (49) 18 (40) 5 (26)
Male 146 (54) 105 (51) 27 (60) 14 (74)
Donor sex (%) .364
Female 93 (34) 71 (34) 13 (29) 9 (47)
Male 177 (66) 135 (66) 32 (71) 10 (53)
Donorepatient sex (%) .007
Femaleemale 44 (16) 29 (14) 7 (16) 8 (42)
Other 226 (84) 177 (86) 38 (84) 11 (58)
Disease etiology (%) .228
De novo 212 (79) 166 (81) 31 (69) 15 (79)
Secondary 37 (14) 25 (12) 8 (18) 4 (21)
Therapy related 21 (7) 15 (7) 6 (13) 0 (0)
Disease classiﬁcation by cytogenetics (%) .392
Favorable 26 (10) 21 (10) 3 (7) 2 (11)
Intermediate 163 (60) 123 (60) 26 (58) 14 (73)
Poor 77 (29) 59 (29) 16 (35) 2 (11)
Unknown 4 (1) 3 (1) 0 (0) 1 (5)
Time from last chemotherapy
to transplant, days (range)
62 (16-366) 61 (16-366) 76 (66-198) 61 (20-273) .079
Pretransplant bone
marrow cellularity  10% (%)
37 (14) 18 (8.7) 10 (22) 9 (47) <.001
Persistent cytogenetic and/or
molecular abnormalities on
pretransplant bone marrow (%)
37/244 (15) 24/183 (13) 7/42 (17) 6/19 (32) <.001
HCT-CI score (%) .024
Low risk 28 (11) 26 (13) 1 (3) 1 (5)
Intermediate risk 47 (17) 37 (18) 6 (13) 4 (21)
High risk 195 (72) 143 (69) 38 (84) 14 (74)
Conditioning regimen (%) .024
MA 193 (72) 155 (76) 25 (56) 13 (68)
RIC 76 (28) 50 (24) 20 (44) 6 (32)
Unknown 1 (0) 1 (0) 0 (0) 0 (0)
ATG regimen (%) .437
No 206 (76) 160 (78) 31 (69) 15 (79)
Yes 64 (24) 46 (22) 14 (31) 4 (21)
Transplant type (%) .913
MRD 104 (39) 78 (38) 18 (40) 8 (42)
MUD 166 (61) 128 (62) 27 (60) 11 (58)
Stem cell source (%) .195
Peripheral blood 254 (94) 191 (93) 45 (100) 18 (95)
Bone marrow 15 (6) 14 (7) 0 (0) 1 (5)
Immune prophylaxis (%) .801
MTX, MMF, tacrolimus 33 (12) 23 (11) 8 (18) 2 (11)
MTX, tacrolimus 213 (79) 165 (80) 33 (73) 15 (78)
Other* 24 (9) 18 (9) 4 (9) 2 (11)
CMV reactivation (%) .118
Yes 134 (50) 97 (47) 24 (53) 13 (68)
No 136 (50) 109 (53) 21 (47) 6 (32)
MA indicates myeloablative; ATG, antithymocyte globulin; MRD, matched related donor; MUD, matched unrelated donor; RIC, reduced intensity and non-
myeloablative; MTX, methotrexate; MMF, mycophenolate mofetil; CMV, cytomegalovirus.
* Other includes cyclosporine and sirolimus.
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ﬂudarabine, cytarabine, ﬁlgrastim (FLAG)-based regimens
were less commonly used in the CR cohort than in the MLFS
and CRp cohorts. These results are summarized in Table 2.
Three-Year OS and EFS
Median follow-ups for the CR, CRp, andMLFS cohorts were
524, 410, and 290 days, respectively. The upper panel of
Figure 1 describes the differences in OS using data from all
patients, and the 3-year OS rates for the CR, CRp, and MLFS
cohorts were 49%, 46%, and 47%, respectively (P ¼ .88). After
adjusting for the effects of other demographic and clinical
characteristics using propensity-score matching, we did not
ﬁnd any signiﬁcant difference in 3-year OS rates between the
MLFS and CR cohorts (P ¼ .73). Similarly, we did not ﬁnd any
signiﬁcantdifferencebetween theCRpandCRcohorts (P¼ .62).The lower panel of Figure 1 describes the differences in EFS
using data fromall patients, and the3-year EFS rates for the CR,
CRp, and MLFS cohorts were 45%, 36%, and 40%, respectively
(P¼ .53). After propensity-scorematching, we did not ﬁnd any
signiﬁcant difference in EFS between theMLFS and CR cohorts
(P ¼ .84). Similarly, we did not ﬁnd any signiﬁcant difference
between the CRp and CR cohorts (P ¼ .40).
NRM, Relapse, and GVHD
The cumulative incidence of relapse in the MLFS cohort
was 11%, signiﬁcantly lower than 36% (P¼ .03) for those in CR
and 47% (P ¼ .004) for those in CRp (Figure 2). However, the
cumulative incidence of NRM in the MLFS cohort was 58%,
signiﬁcantly higher than 22% (P ¼ .0004) for those in CR and
16% (P ¼ .002) for those in CRp (Figure 2). Within the MLFS
cohort, 8 of 13 patients (62%) who received myeloablative
Figure 2. Cumulative incidences of relapse and NRM for the 3 cohorts.
Table 2
Last Chemotherapy before Transplantation
No. of
Patients
in CR
No. of
Patients
in CRp
No. of
Patients
in MLFS
P
MEC 27 (13) 5 (11) 2 (11) <.001
HiDAC 92 (45) 16 (36) 1 (5)
CLAG or CLAG-M 4 (2) 4 (9) 1 (5)
FLAG, FLAG-I, FLAG-IM 11 (5) 7 (16) 3 (16)
Decitabine 11 (5) 2 (4) 2 (11)
Other* 61 (30) 11 (24) 10 (52)
MEC indicates mitoxantrone, etoposide, cytarabine; HiDAC, high-dose
cytarabine; CLAG, cladribine, cytarabine, ﬁlgrastim; CLAG-M, CLAG plus
mitoxantrone; FLAG-I, FLAG plus idarubicin; FLAG-IM, FLAG-I plus gemtu-
zumab ozogamicin.
Values in parentheses are percents.
* Other includes clofarabine, all-trans retinoic acid, sorafenib, plerixafor,
5þ2, 7þ3, gemtuzumab ozogamicin alone, mitomycin, imatinib, and
azacitidine.
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tients (50%) who received RIC (P > .99). The causes of death
included infection, sepsis, recurrence or progression of leu-
kemia, graft failure, and aGVHD and cGVHD. There was a
higher percentage of patients in the MLFS cohort who died
from causes other than GVHD, infection, sepsis, graft failure,
and relapse or progression of leukemia. Those deaths
included 2 from multiple organ failure, 1 from accidental
death, 1 from sinusoidal obstruction syndrome, 1 from car-
diac arrest, and 1 from unknown cause. Two of these deaths
(1 cardiac arrest, 1 sinusoidal obstruction syndrome)
occurred before remission and engraftment were docu-
mented. The results are summarized in Table 3.
The cumulative incidences of grades II to IV aGVHD in the
CR, CRp, and MLFS cohorts were 38%, 38%, and 42%, respec-
tively (P ¼ .93). Likewise, the cumulative incidences ofFigure 1. OS and EFS stratiﬁed for the 3 cohorts.cGVHD in patients in the CR, CRp, and MLFS cohorts were
34%, 38%, and 16%, respectively (P ¼ .22).DISCUSSION
Our results suggest that AML patients in CRp or MLFS
before allo-HCT have similar OS and EFS compared with
patients in CR, suggesting that hematologic recovery after
pretransplant chemotherapy does not signiﬁcantly inﬂuence
survival outcomes. As previously mentioned, studies have
shown that CR with incomplete hematologic recovery is
associated with reduced OS and increased risk of relapse
[13,15-19]. However, these studies did not include outcomes
in AML patients with MLFS inwhich neither ANC nor platelet
count has recovered. Our results seem to suggest that allo-
HCT overcomes the negative impact that poor hematologicTable 3
Causes of Death
Cause of Death No. of
Patients
in CR
No. of
Patients
in CRp
No. of
Patients in
MLFS
P
aGVHD 13 (12) 0 (0) 3 (24) .012
cGVHD 6 (5) 3 (12) 0 (0)
Infection or sepsis 17 (15) 3 (12) 2 (15)
Relapse or progression
of disease
59 (53) 17 (65) 2 (15)
Graft failure 1 (1) 1 (4) 0 (0)
Other* 15 (14) 2 (7) 6 (46)
Total 111 26 13
Values in parentheses are percents.
* Other includes multiple organ failure, sinusoidal obstruction syndrome,
cardiac arrest, intracranial hemorrhage, and unknown.
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study by Sievers et al. [32] showed similar OS in
gemtuzumab-treated patients who received allo-HCT,
whether or not they were in CR or CRp.
It is not clear why there was a higher incidence of NRM in
our MLFS cohort. One possibility is the type of conditioning
regimen before allo-HCT, because there seems to be a higher
rate of NRM in patients who received myeloablative
conditioning compared with those who received non-
myeloablative or RIC, although this did not reach statistical
signiﬁcance, possibly due to the small cohort size. There was
also a higher percentage of female donor-to-male recipient
transplants in our MLFS cohort, which could have also
contributed to high NRM in this cohort, consistent with a
recent published study [33]. Furthermore, differences in
HCT-CI or performance status were unlikely to have
contributed to higher NRM in MLFS patients because we did
not ﬁnd any signiﬁcant differences in these measures among
the 3 cohorts. Similarly, there is no obvious explanation for
the lower relapse rates seen in this cohort, although it is
possible that use of myeloablative conditioning regimens
and female donor-to-male recipient transplants also
contributed to lower relapse rates in these patients.
There are possible explanations why some patients have
poor hematologic recovery after chemotherapy, including
the number of pre-existing comorbidities, type of chemo-
therapy used, and the persistence of cytogenetic and/or
molecular abnormalities on pretransplant bone marrow. Our
CR cohort had the lowest percentage of patients with an
HCT-CI score of 3 or greater. There was also a signiﬁcant
difference in the distribution of types of chemotherapy reg-
imens used in our 3 cohorts. Some chemotherapy regimens
might be more myelosuppressive than others. In fact, Martin
et al. [17] showed that the addition of gemtuzumab ozoga-
micin to FLAG plus idarubicin chemotherapy was associated
with more thrombocytopenia with a CRp rate of 27%
compared with 13% in patients who underwent FLAG plus
idarubicin by itself. Furthermore, failure to recover counts
might be a harbinger of residual leukemia, as suggested by a
higher percentage of patients in our MLFS cohort with
persistent cytogenetic and/or molecular abnormalities.
Several studies have shown the negative impact of minimal
residual disease on post-transplant outcomes in AML pa-
tients [34-36]. We did not assess the pretransplant minimal
residual disease status in any of the patient cohorts, which
could have potentially inﬂuenced our results.
In summary, our results suggest that in AML patients
undergoing allo-HCT, degree of hematologic recovery after
pretransplant chemotherapy has no signiﬁcant effect on
survival outcomes. Thus, it might not be necessary towait for
a prolonged period of time for complete hematologic re-
covery before transplant, thereby mitigating the potential
risk of infectious and noninfectious complications that are
relatively common in patients with prolonged cytopenias.
Furthermore, MLFS in AML patients could indicate persis-
tence of cytogenetic and/or molecular abnormalities. Lower
relapse rates observed in our MLFS cohort are encouraging;
however, the higher incidence of NRM (>50%) suggests that
allo-HCT might best be reserved for MLFS patients who still
have good performance status and low comorbidity scores.
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